Olmesartan medoxomil

Drugs

Volumn 62, Issue 9, 2002, Pages 1345-1353

  Warner, Gregory T ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTACID AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; BACKACHE; BLOOD PRESSURE MONITORING; BRONCHITIS; CLINICAL TRIAL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; NONHUMAN; PHARYNGITIS; REVIEW; RHINITIS; SINUSITIS; STRUCTURE ANALYSIS; SYSTOLIC BLOOD PRESSURE; TITRIMETRY; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0036071006     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262090-00005     Document Type: Review

References (34)

1. Daily regimen and compliance with treatment
2. Time to patient discontinuation of antihypertensive drugs in different classes
3. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
4. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist
5. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade on nitric oxide synthesis in rats
6. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis
7. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats
8. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist
9. Effects of CS-866 on hypertensive nephropathy in SHR and DOCA rats
10. Anti-atherosclerotic efficacy of olmesartan
11. Dose-response relationship of the oral angiotensin II-antagonist CS-866 in healthy male subjects
12. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients
13. The effect of an antacid (aluminum magnesium hydroxide) on the pharmacokinetics and safety of the oral antiotensin II-antagonist CS-866 in healthy, male subjects
14. Steady state pharmacokinetics of CS-866, a novel angiotensin II-receptor antagonist in elderly and young hypertensive patients
15. Pharmacokinetics of the new oral angiotensin II-antagonist CS-866
16. Pharmacokinetics of RNH-6270, the active metabolite of the oral angiotensin II-antagonist CS-866, in healthy, male subjects
17. The pharmacokinetic profile of CS-866
18. Pharmacokinetic, safety and tolerability studies of the oral angiotensin II-antagonist olmesartan medoxomil in young, elderly and verly elderly patients with hypertension
19. A comparative pharmacokinetic, safety and tolerability trial of the oral angiotensin II-antagonist olmesartan medoxomil in subjects with varying degrees of renal impairment and in health volunteers
20. The effect of the combination of the oral angiotensin II-antagonist CS-866 and warfarin on pharmacodynamics, pharmacokinetics and safety in healthy, male subjects
21. The effect of the oral angiotensin II-antagonist olmesartan medoxomil on the safety, tolerability and pharmacokinetics of digoxin in healthy, male subjects
22. Safety, tolerability and efficacy of the new oral angiotensin II (AT1)-receptor antagonist CS-866 in patients with mild to moderate hypertension
23. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects
24. CS-866 (angiotensin-II receptor antagonist): A double-blind study using ambulatory blood pressure monitoring in hypertensive patients
25. Antihypertensive efficacy of CS-866, a novel angiotensin-II antagonist
26. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension
27. A comparison of the efficacy and safety of the oral angiotensin II-antagonist olmesartan medoxomil with those of atenolol in patients with moderate to severe hypertension under continuous treatment with hydrochlorothiazide
28. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension
29. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus losartan in patients with mild to moderate essential hypertension
30. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension
31. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives
32. Dose related differences in blood pressure response are not related to adverse event incidence
33. Clinical studies of CS-866, the newest angiotensin II receptor antagonist